K. Yonemori

发表

Shallow whole genome sequencing approach to detect Homologous Recombination Deficiency in the PAOLA-1/ENGOT-OV25 phase-III trial

D. Stoppa-Lyonnet, C. Callens, S. Cecere, 2023, Oncogene.

Safety, tolerability, pharmacokinetics, and antitumor activity of adavosertib in Japanese patients with advanced solid tumors: A phase I, open-label study.

M. Sugeno, T. Kawata, Shunsuke Kondo, 2024, Cancer treatment and research communications.

Efficacy and safety of nivolumab monotherapy in patients with unresectable clear cell sarcoma and alveolar soft part sarcoma (OSCAR Trial/NCCH1510).

K. Nakamura, T. Nishikawa, M. Kawasaki, 2024, Cancer.

Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial

T. Bachelot, G. Bianchini, S. Hurvitz, 2024, Nature medicine.

Potential utility of pretreatment serum miRNAs for optimal treatment selection in advanced high-grade serous ovarian cancer.

Junichiro Miura, H. Yoshida, J. Kawauchi, 2024, Japanese journal of clinical oncology.

Folate Receptor Alpha Expression and the Tumor Immune Microenvironment in Patients with Cervical Cancer.

E. Noguchi, T. Shimoi, M. Ishikawa, 2024, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.